Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05996458 |
Other study ID # |
KY20232111-F-1? |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 1, 2023 |
Est. completion date |
June 30, 2033 |
Study information
Verified date |
July 2023 |
Source |
Xijing Hospital |
Contact |
rong zheng |
Phone |
19829758242 |
Email |
zhengrong4956[@]163.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
To establish combined gastroenteroscopy screening and follow-up management for
gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of
combined screening for esophagus, stomach and colorectal cancer
Description:
group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood
test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and
SEPTIN9 gene methylation test, and investigation of risk factors, including past disease
history, alcohol drinking history, smoking history, tea drinking history, family history of
cancer, marital and reproductive status, and dietary habits.
group two: The screening population will undergo investigation of risk factors, a fecal
occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool
occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene
methylation testing will be scheduled. If the gene methylation test is positive, a
colonoscopy will be scheduled.
Group one's control(Spouse or sibling of group one);group two's control(Spouse or sibling of
group one): Only the risk factors will be investigated, including previous disease history,
drinking history, smoking history, drinking history, family history of malignant tumor,
marriage and childbearing status, eating habits, etc.
Finally, 10 years follow-up will be conducted to observe the outcome